Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins

Gene Therapy

Volumn 20, Issue 1, 2013, Pages 16-23

  Enkirch, T ^a   Kneissl, S ^b   Hoyler, B ^a   Ungerechts, G ^c   Stremmel, W ^a   Buchholz, C J ^b   Springfeld, C ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

lentivirus; targeting; Tupaia paramyxovirus

Indexed keywords

CD20 ANTIGEN; ENVELOPE PROTEIN; HEMAGGLUTININ; HYBRID PROTEIN; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PARAMYXOVIRUS; PRIORITY JOURNAL; SCANDENTIA; VIRUS ENTRY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD20; B-LYMPHOCYTES; GENETIC VECTORS; HEMAGGLUTININS, VIRAL; HUMANS; LENTIVIRUS; MOLECULAR SEQUENCE DATA; PARAMYXOVIRIDAE; PROTEIN STRUCTURE, TERTIARY; TRANSFORMATION, GENETIC; TUPAIA; VIRAL FUSION PROTEINS;

ANIMALIA; LENTIVIRUS; MEASLES VIRUS; PARAMYXOVIRIDAE; TUPAIA PARAMYXOVIRUS;

EID: 84871964183     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.209     Document Type: Article

References (36)

1. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711-738 (Pubitemid 40995522)
2. Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy-success is finally mounting. Discov Med 2010; 9: 105-111
3. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009; 157: 153-165
4. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573-587 (Pubitemid 47077278)
5. Navaratnarajah CK, Leonard VH, Cattaneo R. Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. Curr Top Microbiol Immunol 2009; 329: 59-76
6. Cattaneo R. Paramyxovirus entry and targeted vectors for cancer therapy. PLoS Pathog 2008; 6: e1000973
7. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540 (Pubitemid 351850977)
8. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T et al. Antibody-targeted cell fusion. Nat Biotechnol 2004; 22: 331-336 (Pubitemid 38295767)
9. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-214 (Pubitemid 40255331)
10. Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008; 118: 2448-2458 (Pubitemid 351949773)
11. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumorsecreted matrix metalloproteinases. Cancer Res 2006; 66: 7694-7700 (Pubitemid 44289228)
12. Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KM, Cattaneo R et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res 2010; 70: 7620-7629
13. Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010; 88: 620-625
14. Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16: 1427-1436
15. Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008; 112: 4843-4852
16. Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Therapy 2009; 16: 700-705
17. Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009; 114: 3173-3180
18. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010; 7: 929-935
19. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010; 18: 477-490
20. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823
21. Miest TS, Yaiw KC, Frenzke M, Lampe J, Hudacek AW, Springfeld C et al. Envelope-chimeric entry-targeted Measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011; 19: 1813-1820
22. Springfeld C, von Messling V, Tidona CA, Darai G, Cattaneo R. Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavageactivation restricts Tupaia paramyxovirus tropism. J Virol 2005; 79: 10155-10163 (Pubitemid 41098556)
23. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514-3520 (Pubitemid 37419939)
24. Bratt MA, Gallaher WR. Preliminary analysis of the requirements for fusion from within and fusion from without by Newcastle disease virus. Proc Natl Acad Sci USA 1969; 64: 536-543
25. Buchholz CJ, Mühlebach MD, Cichutek K. Lentiviral vectors with measles virus glycoproteins-dream team for gene transfer? Trends Biotechnol 2009; 27: 259-265
26. Lamb RA, Parks GD. Paramyxoviridae: The Viruses and Their Replication. Fields Virology, 5th edn. Lippincott Williams & Wilkins: Philadelphia, 2007: 1449-1496
27. Tidona CA, Kurz HW, Gelderblom HR, Darai G. Isolation and molecular characterization of a novel cytopathogenic paramyxovirus from tree shrews. Virology 1999; 258: 425-434 (Pubitemid 29390252)
28. von Messling V, Milosevic D, Devaux P, Cattaneo R. Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol 2004; 78: 7894-7903 (Pubitemid 38944275)
29. Kobayashi M, Iida A, Ueda Y, Hasegawa M. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003; 77: 2607-2614 (Pubitemid 36222785)
30. Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Pluckthun A, et al. DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 2011; 19: 686-693
31. Frecha C, Levy C, Cosset FL, Verhoeyen E. Advances in the field of lentivectorbased transduction of T and B lymphocytes for gene therapy. Mol Ther 2010; 18: 1748-1757
32. Frecha C, Levy C, Costa C, Negre D, Amirache F, Buckland R et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 2011; 85: 5975-5985
33. Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ. Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology 2011; 413: 149-152
34. Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62-72 (Pubitemid 36305359)
35. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94: 10319-10323 (Pubitemid 27407039)
36. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875